Lavandulyl acetate is an irregular monoterpene ester strongly associated with lavender chemistry, especially as a secondary floral-fruity marker behind the better known linalyl acetate. The strongest live evidence supports identity, repeated occurrence in lavender oils, biosynthetic relevance, fragrance-safety review, and a narrower preclinical literature that includes mosquito-larvicidal testing. AromaForge should present it mainly as a chemistry-and-aroma constituent with emerging isolated-compound data rather than as a health-outcome ingredient.
Chemical identity and composition
PubChem identifies lavandulyl acetate as the acetate ester of lavandulol. The lavender biosynthesis literature places lavandulol and lavandulyl acetate in the same irregular-monoterpene branch, and newer microbial engineering work shows lavandulyl acetate can be formed by acetylating lavandulol through an alcohol acyltransferase step.
Aroma and practical use
- Use the recorded floral, lavender-like, fruity, sweet, fresh-herbal descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2016 entomology study reported that lavandulyl acetate was more toxic to mosquito larvae than bicyclogermacrene, with LC50 values of 4.17 microg/mL for Anopheles subpictus, 4.60 microg/mL for Aedes albopictus, and 5.11 microg/mL for Culex tritaeniorhynchus.
A 2016 entomology study reported that lavandulyl acetate was more toxic to mosquito larvae than bicyclogermacrene, with LC50 values of 4.17 microg/mL for Anopheles subpictus, 4.60 microg/mL for Aedes albopictus, and 5.11 microg/mL for Culex tritaeniorhynchus.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2026 E. coli engineering study established de novo biosynthesis of lavandulyl acetate and achieved a final titer of 89.43 mg/L after pathway and fermentation optimization.
A 2026 E. coli engineering study established de novo biosynthesis of lavandulyl acetate and achieved a final titer of 89.43 mg/L after pathway and fermentation optimization.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedRIFM published a dedicated fragrance safety assessment for lavandulyl acetate in 2021, which provides a stronger public safety anchor than most lavender-minor-constituent records have.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
The direct isolated-compound activity literature located in this pass is preclinical and non-clinical, so archive language should stay chemistry-forward and non-medical.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
acetylation of lavandulol by alcohol acyltransferase
A 2026 microbial biosynthesis paper identified Saccharomyces cerevisiae ATF1 as an effective enzyme for acetylating lavandulol to lavandulyl acetate in an engineered pathway.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
larvicidal toxicity to mosquito larvae
The direct isolated-compound vector paper supports lavandulyl acetate as toxic to mosquito larvae at low microgram-per-mL LC50 values, indicating clear entomological activity without implying human therapeutic relevance.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- This pass did not verify an isolated lavandulyl-acetate human clinical literature base.
- Most directly accessible standalone evidence is fragrance safety, biosynthesis, or vector-control research rather than human-use pharmacology.
- A constituent-specific public dermal threshold for lavandulyl acetate was not verified in the reviewed sources.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.